Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder

By Frank Vinluan – MedCity News –

Neurotech Pharmaceuticals’ surgically implanted cell and gene therapy, Encelto, is now FDA approved to treat macular telangectasia type 2 (MacTel). It’s the first therapy for this rare retinal degeneration disorder.

Protein therapies for the eye must be dosed as frequent injections. Gene therapy offers one-time treatment, but must also be administered by injection. Neurotech Pharmaceuticals’ gene therapy comes in a surgical implant, and it’s now the first FDA-approved treatment for a rare vision-loss disorder.

Read the full article by clicking here